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IS THERE A GENETIC BASIS FOR ALCOHOLISM? 
David Aharonoff 
ABSTRACT 
This paper reviews studies done on the correlation of alcoholism and genetics. 
Evidence of this correlation can be seen in high heritability of alcoholism. The main methods 
used in determining genetic risk factors are candidate gene studies and genome wide studies. 
This review focuses mainly on findings related to specific neurotransmitters and receptors in 
relation to alcoholism. Evidence has shown that specific neurotransmitters and receptors can 
play a role in increased susceptibility to alcoholism. The neurotransmitters and receptors 
discussed in this paper include GABA, glutamate, and endogenous opioids. There is also a 
discussion focused on mutations of specific enzymes (ADH and ALDH) used to metabolize 
alcohol and its possible effects on developing alcoholism. When applicable, findings include a 
potential pharmacological treatment targeting the possible causation for alcoholism. Results 
from the studies conducted by the Collaborative Studies on Genetics of Alcoholism (COGA) 
have been discussed as well. COGA findings include specific chromosomes and their 
relationships with alcoholism, namely 1, 4 , 7, 11, and a possible indicator for increased 
susceptibility, or level of response (LR).  
The World Health Organization (WHO) estimates that alcohol results in 2.5 million 
deaths each year and in 9% of all deaths between the ages of 15 and 29.  The WHO further 
concludes that alcohol is the world’s third largest risk factor for disease burden; it is the 
leading risk factor in the Western Pacific and the Americas, and the second largest in Europe 
(World Health Organization 2011). An American survey by Hasin and colleagues (2007) 
concludes that alcoholism affects 4-5 % of the population at any given time. As a result of these 
widespread ramifications, alcoholism has been a subject of much research.  This paper will 
primarily deal with the studies of genetic influences that affect alcoholism risk. Locating a 
genetic link can lead to possible alcoholism prevention of those genetically susceptible and help 
better treat those who have already developed the problem. 
DISCUSSION 
In order for researchers to compare and contrast their findings, they must agree 
on the definition of an alcoholic. Most researchers rely on the definition of the 
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, [DSM-IV] 
(APA 1994) and the World Health Organization’s International Classification of 
Diseases (ICD-10). The Diagnostic and Statistical Manual of Mental Disorders of the 
American Psychiatric Association, fourth edition (DSM-IV) defines alcohol 
dependence, to be equated with alcoholism, as: 
 A maladaptive pattern of substance use, leading to clinically significant 
impairment or distress, as manifested by three (or more) of the 
following, occurring at any time in the same 12-month period: 
1. Tolerance, as defined by either of the following: 
• A need for markedly increased amounts of the substance to achieve 
intoxication or desired effect. 
• Markedly diminished effect with continued use of the same amount of 
substance. 
2. Withdrawal, as manifested by either of the following: 
• The characteristic withdrawal syndrome for the substance. 
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• The same (or a closely related) substance is taken to relieve or avoid 
withdrawal symptoms. 
3. The substance is often taken in larger amounts or over a longer period 
than was intended. 
4. There is a persistent desire or unsuccessful efforts to cut down or 
control substance use. 
5. A great deal of time is spent in activities to obtain the substance, use 
the substance, or recover from its effects. 
6. Important social, occupational or recreational activities are given up 
or reduced because of substance use. 
7. The substance use is continued despite knowledge of having a 
persistent or recurrent physical or psychological problem that is likely to 
have been caused or exacerbated by the substance (e.g., continued 
drinking despite recognition that an ulcer was made worse by alcohol 
consumption). 
The ICD-10 criteria for alcoholism are similar to that of the DSM-IV (Baber 
1992). A main difference is that ICD-10 doesn’t include a category on alcohol abuse, 
but rather refers to the same diagnosis as “harmful use.” The change is meant to 
prevent an underreporting of alcohol abuse (Baber 1992). “Harmful use” includes 
psychical or mental damage due to alcohol dependence (Baber 1992).  
A possible indication that a genetic predisposition for alcoholism exists is the 
fact that an alcoholic’s biological offspring are approximately three to five times more 
likely to develop alcoholism during their lifetime than the biological offspring of 
nonalcoholics (Cotton 1979).  One can argue, however, that the increased rate of 
alcoholism in alcoholics’ biological offspring is due to environmental influences; a 
positive family history can merely be the result of shared environmental influences. 
Therefore, behavioral geneticists use twin and adoption studies to identify the separate 
contributions of genetics and shared environmental factors. 
 Researchers use analyses of genetically identical monozygotic twins (MZ) and 
fraternal dizygotic (DZ) twins to measure the heritability of alcoholism.  There are 
eight major twin studies of alcoholism in men, and in all but one of these studies the 
concordance (same trait in both members of a pair of twins) rate for alcoholism was 
significantly greater in MZ than DZ twins (McGue1999). For example, in a study by 
Kendler, Prescott, Neale, and Pedersen (1997) on 8,939 Swedish male twins born from 
1902 to 1949, the MZ twin concordance rate is significantly higher than the DZ twin 
concordance rate. Overall, the studies’ concordance rates in monozygotic twins are 
approximately 47.9%, and in dizygotic twins, 32.8%.  
Adoption studies also allow researchers to better separate genetics from 
environmental influences on the development of alcoholism. Seminal research by 
Cloninger and colleagues (1987) uses a large-scale adoption study in Sweden to 
identify genetic and other variables that predict alcohol abuse in adoptees.  This study, 
coined the Stockholm Adoption Study, was done on 862 men and 913 women adopted 
by non-relatives at an early age in Sweden.  The study distinguishes between two 
forms of alcoholism: Type I is characterized as late onset of alcoholism, after age 25, 
and marked by frequent psychological dependence; Type II alcoholism is 
characterized as a relatively early onset of alcoholism, before age 25, and marked by 
spontaneous alcohol seeking and aggressive behavior.  Analysis of data from male 
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adoptees shows that although Type II alcoholism has an approximate heritability of 
90%, Type I alcoholism has a heritability estimate of less than 40%. Many of the key 
results from the original Stockholm Adoption Study were independently replicated in 
a second Swedish city, Gothenburg (Sigvardsson et al. 1996).  The replication study 
was carried out on a slightly smaller group (577 men and 660 women) but concludes 
that the risk of Type 2 alcoholism is increased 6-fold in adopted sons with a Type 2 
genetic background compared with others, while Type I alcoholism has only a 4-fold 
increase in adopted men with Type I genetic backgrounds of alcoholism.  
 Due to the evidence that alcoholism is heritable, the next step is to identify the 
possible genetic factors that lead to the heritability. Two basic strategies are used to 
identify genetic risk factors for alcoholism: candidate gene approach and genome-wide 
studies (Sloan et al. 2008). The candidate gene approach involves assessing the 
association between a particular allele (or set of alleles) of a gene that may be involved 
in the disease (i.e. a candidate gene) and the disease itself (Kwon and Goate 2000).  
This approach often begins with the knowledge of potential physiological mechanisms 
that might be related to the endophenotype and makes educated guesses about which 
of the known genes might be important (Schuckit 2000). The genes most extensively 
examined by candidate gene studies are those involved in alcohol (i.e. ethanol) 
metabolism and in neurological pathways responsible for increased risk taking and 
“reward” stimulation from ethanol (Sloan et al. 2008).  
A genome-wide study scans all genomes of individuals and identifies genetic 
polymorphisms. The two main approaches to genome-wide analysis are association and 
linkage (Sloan et al. 2008). Association studies examine genetic polymorphisms 
associated with case or control status, whereas linkage studies investigate the 
inheritance of specific locations on a chromosome within family lines (Sloan et al. 
2008). In association studies, one tests if a given allele contributes to the risk for 
alcohol dependence. For example, if a researcher hypothesizes that Gene A plays a role 
in alcoholism, he would expect this allele to differ between the case and the control 
subjects.  
Linkage analysis scans the genome using a type of genetic variation called 
microsatellites. Microsatellites are nucleotide pair combinations of DNA which repeat 
themselves and form groupings. Microsatellites can be highly polymorphic, making 
them useful for comparative genetic studies of organisms. Then, the pattern of 
transmission of disease (e.g. alcoholism) in families with multiple affected members is 
compared with the pattern of transmission of certain microsatellites (Foroud et al. 
2010). The principal hypothesis in linkage analysis is that alcoholics within a family 
share many risk alleles; therefore, genes containing alleles that increase the risk for 
alcoholism reside within chromosomal regions that are inherited by most or all 
alcoholic family members (Foroud et al. 2010). 
A prime example of specific genes related to the risk of alcoholism are those 
that control the production of the enzymes that metabolize ethanol (i.e. alcohol). 
Ethanol is metabolized in the liver, where it is converted to acetaldehyde by the 
enzyme alcohol dehydrogenase (ADH). ADH is responsible for 80% of ethanol’s 
metabolism to acetaldehyde (Gemma et al. 2006). About 10% of ethanol is metabolized 
by CYP2E1; the percentage increases when ADH is saturated (Gemma et al. 2006). 
Acetaldehyde is then converted to acetate by the enzyme aldehyde dehydrogenase 
(ALDH).  High levels of acetaldehyde in the blood causes nausea, dizziness, and 
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headaches; therefore, variation in the genes coding for the ADH and ALDH enzymes 
are expected to be associated with alcoholism risk (Edenberg 2007).  
There are at least six isoenzymes of ALDH (Schuckit 2000).  ALDH2*2, an 
isoenzyme of ALDH, involves a point mutation that results in the exchange of the 
amino acid glutamate at position 487 of the ALDH protein for the amino acid lysine 
(Edenberg 2007; Foroud et al. 2010). This mutation acts in a nearly dominant manner 
to render the enzyme almost inactive (Foroud et al. 2010). As a result, homozygous 
carriers of ALDH2-2 exhibit highly elevated levels of acetaldehyde, which produces 
aversive reactions, including flushing, tachycardia and nausea after consuming even a 
small amount of alcohol (Eng et al. 2007).  Studies have shown that ALDH2-2 
influences a person’s drinking levels, and, consequently, the risk of developing alcohol 
abuse or dependence (Edenberg 2007; Hurley et al. 2002). There are almost no 
documented cases of homozygous carries of ALDH2-2 being diagnosed as alcoholics 
(Luczak et al. 2006). Even people who are heterozygous for this mutation produce an 
ALDH enzyme with extremely low enzyme activity (Crabb et al. 1989).  
Approximately 10% of Asian men and women (e.g. Japanese, Chinese, and 
Koreans) are homozygous for the mutation of ALDH2*2, although it is not known to 
be found in any other racial group (Wall and Ehlers 1995). An additional 40% of 
Asians are heterozygotes for the ALDH mutated enzyme (Wall and Ehlers 1995). 
Compared with a Chinese man carrying two active ALDH alleles, the odds ratio of an 
alcoholism risk for a Chinese man carrying one inactive ALDH2-2 allele is 0.33 
(Edenberg 2007). Furthermore, although heterozygote ALDH2-2 carriers represent 
almost half of the general population in their countries, they comprise less than 10% of 
Asian alcoholics, further supporting the conclusion that even heterozygotes have a 
relative protection from alcoholism (Murayama et al. 1998). 
There are also coding variations in the ADH gene, called ADH2-2 and ADH2-
3, which encode highly active enzymes which increase the production rate of 
acetaldehyde (Li 2000). These variations also reduce the risk for alcohol dependence 
(Edenberg 2007; Thomasson et al. 1991). For example, a pilot study by Neumark and 
colleagues (1998) was the first example of association between alcohol consumption 
patterns and a polymorphism at the ADH2 locus in a Jewish population. The study 
compares ADH loci in 92 non-drinkers (control) versus 53 heavy drinkers 
(case).  Neumark furthered the study in 2004 by testing the effect of ADH2-2 on 
alcohol-elimination rates (AER) under experimental conditions. The study is based on 
the above-cited hypothesis that ADH2-2 increases the rate at which alcohol is 
metabolized, thereby increasing the production rate of acetaldehyde and producing 
aversive reactions. The study confirms that the rate of alcohol elimination is 
significantly associated with the ADH2 genotype of Jewish males (Neumark 2004). 
The evidence that an increase of acetaldehyde can be a deterrent to the 
development of alcohol abuse has led researchers to develop pharmacological 
treatments. Disulfiram blocks the enzyme aldehyde dehydrogenase, leading to an 
accumulation of acetaldehyde following an intake of alcohol (Heilig and Egli 2006). 
The accumulation of acetaldehyde then causes flushing, shortness of breath, 
tachycardia and other unpleasant symptoms. The point of disulfiram is not that 
patients actually experience adverse symptoms, but that that the anticipation of these 
symptoms helps patients abstain from consuming alcohol (Heilig and Egli 2006). The 
logic is that an accumulation of acetaldehyde poses a possible medical risk. However, 
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disulfiram has a limited and largely negative documentation for efficacy (Heilig and 
Egli 2006). For example, a controlled multisite study of disulfiram treatment of 
alcoholism in 605 men concludes that although disulfiram may help reduce drinking 
frequency after relapse, it does not reduce the probability of abstinence from alcohol 
(Fuller et al. 1986). 
Researchers have also done candidate gene studies on genes for receptors in the 
neurotransmitter gamma-aminobutyric acid (GABA), opioid receptor and components 
of the pathways for the neurotransmitters serotonin, dopamine, and glutamate (Sloan 
et al. 2008). A full discussion of each neurotransmitter surpasses the scope of this 
paper; therefore, but a few neurotransmitters and receptors and their relation to 
alcoholism will be discussed.    
There is evidence supporting a link between the endogenous opioid system and 
excessive alcohol consumption (Gianoulakis 2001; Herz 1997). This evidence, linking 
the endogenous opioid system to alcoholism, led to several theories regarding the 
possible nature of an opioid abnormality in this disorder (Oswald and Wand 2004). 
The Opioid Deficit Hypothesis postulates that physiological cravings for alcohol may 
be the result of a deficiency of naturally occurring opiate like substances 
(Trachtenberg and Blum 1987). Conversely, the Opioid Surfeit Hypothesis maintains 
that excess (i.e. surfeits), not deficits, in opioidergic activity increases one’s propensity 
to consume alcoholic beverages (Reid et al. 1991).  
The first study to suggest a possible link between endogenous opioid and 
ethanol was conducted by Davis and Walsh (1970), who discovered that morphine-
like alkaloids (tetrahydroisoquinolones) are formed in vivo as a result of the 
interaction between ethanol metabolite, acetaldehyde, and certain metabolites of 
dopamine. Due to Davis and Walsh’s findings, further research sought to demonstrate 
that these alkaloids could bind to opioid receptors and produce opioid-like effects 
(Blum et al. 1978; Fertel et al. 1980). However, the pharmacological relevance of these 
compounds in opioidergic processes remains unclear because their concentrations in 
brain tissues is extremely low (Oswald and Wand 2004). 
The best evidence of the linkage between endogenous opioid systems and 
ethanol consumption is that pharmacological blockades of opioid receptors 
reduce alcohol drinking in a dose-related fashion. Naltrexone is an opioid receptor 
antagonist that reduces alcohol cravings and relapses to heavy drinking, but it does not 
necessarily produce total abstinence. The initial study done by Altshuler and 
colleagues (1980) reports on the dose-related effect of naltrexone on decreasing 
ethanol drinking in 10 of 21 rhesus monkeys who were willing to self-administer 
alcohol. The treatment results were replicated by O’Malley et al. in 1992. In a 12-
week, double-blind, placebo-controlled trial conducted on seventy male alcohol-
dependent patients, Volpicelli and colleagues (1992) found that only 23% of alcoholic 
subjects who were administered naltrexone relapsed to heavy drinking, compared with 
54.3% of subjects taking a placebo. Based, in part, on the findings of these studies, 
naltrexone was approved by the Food and Drug administration (FDA) in 1995 for the 
treatment of ethanol dependence. Since naltrexone's approval for the treatment of 
alcoholism, the opioid antagonist has been tested in 29 controlled clinical trials in 
unselected participants with alcoholism (Pettinati et al. 2006). The study concludes 
that “19 (70%) of 27 clinical trials that measured reductions in ‘heavy or excessive 
drinking’ demonstrated an advantage for prescribing naltrexone over placebo, whereas 
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only 9 (36%) of 25 clinical trials that measured abstinence or ‘any drinking’ found an 
advantage for medication over placebo” (Pettinati et al. 2006). 
The effects of naltrexone have led to candidate gene studies on opioid 
receptors. There are three types of opioid receptors (mu, delta and kappa) that 
represent respective targets of the major opioid peptides (Herz 1997). Naltrexone acts 
as an antagonist at opioid receptors, with a relative selectivity for the µ-opioid receptor 
(Oswald and Wand 2004). There are more than 25 identified allelic variants of the 
gene that codes for the µ-opioid receptor (O’Brien 2008). In a human laboratory study 
(Ray and Hutchison 2004), volunteers with Asp40 allele (OPRM1) reported greater 
subjective euphoria at a given ethanol blood level. In a more recent study of heavy 
drinkers, naltrexone attenuated the increased alcohol stimulation in those carrying the 
Asp40 allele (Ray and Hutchison 2007). 
Additionally, GABAergic mechanisms mediate many of the behavioral effects 
of ethanol, including its anticonvulsant, sedative-hypnotic, cognitive-impairing, and 
fine motor skill damaging effects (Kumar et al. 2009). The two classes of GABA 
receptors are GABA-A and GABA-B. GABA-A receptors are ligand-gated ion 
channels (i.e. ionotropic) that confer fast synaptic inhibition (Enoch 2007). GABA-A 
receptors undergo allosteric modulation by several structurally unrelated drugs, most 
with their own binding sites, including ethanol and benzodiazepines (Enoch 2007). 
Initial evidence that alcoholism is related to GABA-A receptors is because 
benzodiazepines show effectiveness in treating alcohol withdrawal (Enoch 2007).  
GABA-A receptors are composed of five subunits (Sigel et al. 2006). Most 
receptors consist of two ! (alpha), two " (beta), and one # (gamma) subunits (Sigel et 
al. 2006). The GABA-A receptor ion channel is lined by the transmembrane (TM) 
segments from each of the five subunits that form the receptor (Enoch 2007). Specific 
mutations in transmembrane domains 2 and 3 of the alpha subunit can abolish or 
markedly reduce the effects of ethanol on these receptors without necessarily affecting 
receptor function; therefore, alcohols may bind in a cavity located between TM2 and 
TM3 (Mascia et al. 2000). 
 Topiramate, which has a complex effect on GABA-A receptors, is 
hypothesized to decrease alcohol reinforcement and the propensity to drink (Johnson 
et al. 2007). A double-blind, randomized, placebo-controlled, 14-week trial of 371 men 
and women concludes that “topiramate was significantly more efficacious than placebo 
at reducing the percentage of heavy drinking days,” and “topiramate is a safe and 
consistently efficacious medication for treating alcohol dependence”( Johnson et al. 
2007).    
GABA inhibits hypothalamic-pituitary–adrenal axis responses to stress whereas 
glutamate activates the response (Herman et al. 2004). Prime targets of ethanol are the 
N-methyl-D-aspartate (NDMA) receptors in the glutamate system (Spanagel 2009). 
NMDA is an amino acid derivative that acts as a specific agonist at the NMDA 
receptor, mimicking the action of glutamate. Acute alcohol exposure inhibits the 
excitatory action of glutamate at the N-methyl-d-aspartate (NMDA) receptor, 
whereas chronic alcoholism results in increased NMDA receptor expression so that 
abrupt withdrawal produces a hyperexcitable state that leads to seizures 
(Guochuan and Coyle 1998). These finding have led to the formulation of the 
glutamate homeostasis hypothesis of addiction which suggests that enhanced 
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glutamate-mediated neuronal excitability during withdrawal and prolonged abstinence 
contributes to craving and relapse (Kalivas 2009).  
Further, “Metabotropic glutamate (mGlu) receptors, which include mGlu1–8 
receptors, are a heterogeneous family of G-protein-coupled receptors which function 
to modulate brain excitability via presynaptic, postsynaptic and glial mechanisms” 
(Schoepp 2001). In contrast to ionotropic receptors, metabotropic receptors influence 
the activity of a cell indirectly by first initiating a metabolic change in the cell. Studies 
provide evidence that activation of group II mGluRs (predominantly presynaptical) by 
a selective mGlu 2/3 agonist (LY379268) dose dependently blocks the effects of both 
stress and drug related environmental stimuli on the recovery of extinguished ethanol-
seeking behavior (Zhao et al. 2006). A similar study on group I mGluRs 
(predominantly located postsynaptically) in alcohol-preferring P-rats, a well-defined 
genetic model of excessive alcohol consumption, shows that infusion of the mGluR5 
antagonist 2-methyl-6(phenylethynyl) pyridine (MPEP) in the nucleus accumbens 
reduces ethanol-reinforced responding (Besheer et al. 2010). Besheer et al. (2010) 
concludes that the data “confirms the importance of mGluR5 activity in the nucleus 
accumbens in regulating drug reinforcement and emphasizes the potential therapeutic 
utility of targeting this receptor system in individuals with genetic risk for excessive 
drinking.”  
The interaction of ethanol and glutamate led to candidate gene studies on 
glutamate. An association study that tested the candidate gene hypothesis of allelic 
variants of the ionotropic glutamatergic N-methyl-D-aspartate receptor (NMDAR) 
provides evidence that they are associated with vulnerability to alcoholism (Wernicke 
et al. 2003). Wernicke and colleagues studied variants of the ionotropic 
glutamatergic N-methyl-d-aspartate receptor (NMDAR the silent G2108A and 
C2664T polymorphisms of the NMDAR1 and the NMDAR2B genes), in exon 5 of 
the EAAT2 gene in 702 subjects of German descent, comprising 367 alcohol-
dependent subjects and 335 control subjects. Genotype frequencies of the NMDAR1 
polymorphism differed significantly between control and alcoholic subjects and the 
NMDAR2B polymorphism revealed a significantly reduced T allele in Cloninger type 
2 alcoholics and in patients reporting an early onset compared with control subjects.  
In 1989, the National Institute on Alcohol Abuse and Alcoholism initiated the 
Collaborative Study on the Genetics of Alcoholism (COGA), a large, systematic effort 
to identify the genes that predispose to alcoholism. COGA’s goal is to elucidate the 
genetic mechanisms that contribute to a person’s susceptibility to alcohol abuse and 
dependence (Begleiter et al. 1995). COGA generated a dataset of 1,857 families 
consisting of 16,062 individuals as of March 2010 (Foroud et al. 2010).  Due to the 
genetic complexity of alcoholism, COGA researchers chose an unbiased survey of the 
entire genome (i.e. genotyping) (Edenberg 2002). Using microsatellite markers, more 
than 1.2 million genotypes were generated on 2,310 people from families of alcoholics 
and 1,238 people from control families (Edenberg 2002). This information enables 
researches to monitor the inheritance pattern of marker alleles within families with 
alcoholics and therefore helps identify chromosomal regions that show genetic linkage 
with alcoholic related traits (Edenberg 2002). To be categorized as a “family of 
alcoholics” the family must comprise at least three first-degree relatives who met 
lifetime criteria for Diagnostic and Statistical Manual of Mental Disorders, Third Edition, 
Revised (DSM–III–R) (Foroud et al. 2010). 
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COGA data collected from families with alcoholism are used for both linkage 
and association analyses (Sloan et al. 2008). In 1998, COGA researchers published 
their initial linkage findings based on an analysis of 291 markers in 987 individuals 
from 105 families (Reich et al. 1998). Substantial evidence points to a susceptibility loci 
for alcohol dependence on chromosomes 1 and 7.  In addition, there is suggestive 
evidence for a protective locus on chromosome 4 near the ADH gene (Reich et al. 
1998). At the same time as the COGA findings were published, a second large-scale 
linkage study of alcoholism, based on a sample of Native Americans, reported 
suggestive evidence of the existence of a predisposing gene on Chromosome 11p, in 
close proximity to the DRD4 dopamine receptor (Long et al 1998). Evidence also 
suggests a protective gene on Chromosome 4p, near the beta1 GABA receptor gene 
(Long et al. 1998). Although only the Chromosome 4 findings overlapped, the two 
studies sampled different ethnic groups, and the genes that underlie alcoholism risk 
might be expected to vary for groups having distinct evolutionary history (McGue 
1999). A more recent COGA study by Yang and colleagues (2005) found potential 
candidate regions on chromosomes 1, 2, and 7 linked with alcoholism susceptibility. 
Overall, Yang viewed his findings as consistent with Reich’s findings (Yang et al. 
2005).  
 Due to prior evidence for the role of the ADH genes in alcoholism 
susceptibility, the COGA investigators did several studies to determine the specific 
nature of the link (Foroud et al. 2010). In one particular study, COGA researches 
genotyped 110 DNA markers known as single nucleotide polymorphisms (SNPs) 
across the seven ADH genes located on chromosome 4q and analyzed their association 
with alcoholism in a set of families (n= 262) with multiple alcoholic members 
(Edenberg et al. 2006). The analyses show strong evidence that 12 SNPs located in 
and around the ADH4 gene are significantly associated with alcoholism (Edenberg et 
al. 2006).  
Evidence of a molecular interaction between ethanol and GABA receptors led 
COGA researchers to study the link between variation in GABA receptors and 
alcoholism. Edenberg and colleagues (2004) performed a linkage analyses of 69 single-
nucleotide polymorphisms (SNPs) within a cluster of four GABA (A) receptor genes 
located in chromosome 4p: GABRG1, GABRA2, GABRA4, and GABRB1. The 
analyses found thirty-one SNPs in GABRA2 associated with alcohol dependence. 
Edenberg concludes his study by stating, “ the convergence of evidence from different 
analyses and phenotypes, along with the biological data on its function, provides 
strong evidence that GABRA2 is a key gene affecting the risk for alcoholism.” 
Interestingly, the GABRA2 is part of the GABA-A ! subunit that was mentioned 
before as a possible binding spot for alcohol.  
The genome-wide association studies (GWAS), also known as the whole 
genome association studies, are examinations of all or most of the genes (the genome) 
of different individuals of a particular species to see how much the genes vary from 
individual to individual. Different variations are then associated with different traits, 
such as diseases. In humans, hundreds or thousands of individuals are tested for 
single-nucleotide polymorphisms (SNPs). The advantage of GWAS is that it allows a 
comprehensive test for associations across the genome, rather than testing only one 
gene at a time.   
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The genome-wide association studies (GWAS) examine up to a millions SNPs 
through the human genome in a single experiment (Foroud 2010). The different 
variations of SNPs between individuals is then associated with different traits, such as 
diseases. An advantage of GWAS is its hypothesis-free strategy and its suitability for 
the discovery of novel genetic contributors to disease (Bierut et al. 2010). 
This first genome-wide significant association study in alcohol dependence was 
published in 2009 (Treutlein et al. 2009). The GWAS included 487 male inpatients 
with alcohol dependence as defined by the DSM-IV and 1,358 population-based control 
individuals (Treutlein et al. 2009). The GWAS tested 524 396 single-
nucleotide polymorphisms (SNPs) (Treutlein et al. 2009).  The analyses found two 
closely linked SNPs located on chromosome 2 (Treutlein et al. 2009). However, a 
recent GWAS of 1,897 European-American and African-American subjects with 
alcohol dependence compared with 1,932 unrelated, alcohol-exposed, nondependent 
controls did not replicate the finding reported by Treutlein and colleagues (Bierut et 
al. 2010). Interestingly, Bierut’s GWAS found SNPs genotyped in GABRA2 that 
overlap with SNPs reported by Edenberg et al. (2004).  
The level of reaction to alcohol has been a useful tool to indicate a possible 
increase in susceptibility to alcoholism. Studies have found a correlation between level 
of response (LR) to alcohol and the risk of developing alcohol dependency (Schuckit 
1999). Numerous alcoholics have reported an ability to consume large amounts of 
alcohol with relatively little effect from early in their drinking careers (Schuckit 1999). 
A low LR is usually evaluated by giving alcohol to individuals and determining the 
intensity of response at a given blood alcohol concentration (BAC), or by indirectly 
measured through a self-report of a history of a higher number of drinks required to 
produce a specific effect (Schuckit 2000). A study of 453 sons of alcoholics and 
controls as conducted over a period of 15 years demonstrated that a low LR was a 
significant predictor of later alcoholism (Schuckit and Smith 1996).   
There are several indications that LR is genetically influenced. For example, a 
study on 3,810 adult twin pairs reported a higher level of similarity on some aspects of 
LR in identical twins than in fraternal twins, with an estimated heritability between 40 
and 60 percent (Martin 1988).  A pilot study (Mazzanti et al. 1999) evaluated 17 men 
with low LR scores, comparing results to 24 individuals who were clearly higher on 
the LR scale. The high LR and low LR groups were then evaluated for the patterns of 
5 candidate genes relating to serotonin and gamma-aminobutyric acid functions. The 
14 men with the LL genotype of the serotonin transporter (5-HTT) polymorphism and 
the seven with the genotype of the GABAA alpha 6 polymorphism had demonstrated 
lower LR scores at about age 20, and had significantly higher proportions of alcoholics 
than the other genotypes for those loci. These studies show that low LR can be a 
potential indicator to a genetic risk of alcoholism.   
CONCLUSION 
In conclusion, evidence has shown that there exists a genetic susceptibility to 
alcoholism. However, it is clear that there are environmental factors, possible as high 
as 50% (Dick and Beirut 2006), that can attribute to alcoholism.  The main focus of 
this paper is to show that the genetic component of alcoholism exists as well, though it 
is clear that alcoholism is a complex disease that involves various mechanisms and 
pathways. Susceptibility to alcoholism cannot be attributed to one single gene, 
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neurotransmitter, or receptor. Other possible neurotransmitters that haven’t been 
discussed but yet can play a vital role are serotonin and dopamine (DRD2). This 
paper is only a brief overview of possible genetic contributions to alcoholism.  There is 
much more research that has been done and more that will be done in the near future. 
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